COVID vaccines: Pfizer, AstraZeneca, Sputnik V more effective than Sinopharm - study
According to the study, which included the data of more than one million people, the Chinese-developed Sinopharm vaccine was less suitable for those over 50 years old.
Vials representing the mRNA coronavirus disease (COVID-19) vaccine candidate developed by Sinopharm's China National Biotec Group (CNBG) are seen displayed at its booth at the 2021 China International Fair for Trade in Services (CIFTIS) in Beijing, China September 3, 2021.(photo credit: REUTERS/FLORENCE LO)ByHUDHAIFA EBRAHIM/THE MEDIA LINE
